Mark D. Pescovitz
Abstract
This chapter focuses on the use of the approved drug rituximab in protocols aimed at controlling B-cell-mediated immunity.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This chapter focuses on the use of the approved drug rituximab in protocols aimed at controlling B-cell-mediated immunity.
Key concepts: Rituximab, Monoclonal antibody, CD20, Monoclonal, Medicine, Immunology, Antibody